Report Details

Global Bladder Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

ID : 7745249
Date : May 2019
Pages : 218 Pages
Industry : Pharmaceutical and Healthcare


Global Bladder Cancer Treatment Market:
Global bladder cancer treatment market estimated to be valued US$ XX Mn in 2018 and poised to grow at CAGR of XX% over 2019-2025. Market for bladder cancer treatment is projected to reach US$ XX Mn by 2025.


Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named as transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma.

 

Increase in incidence rate of bladder cancer cases, technological advancements, drug innovations with regard to the treatment of bladder cancer, government initiatives, the rise in aging of the population, and advanced health care services are expected to drive the market for bladder cancer treatment drugs. In addition, the rise in awareness about bladder diseases, their available therapies in the market, and increase in health care expenditure are driving the global market for bladder cancer treatment drugs. However, the rise in a number of patent expirations, asymptomatic nature of the disease, and rise in the use of generic drugs are some of the major factors restraining the revenue growth of the global bladder cancer treatment drugs market over the forecast period.



Global bladder cancer treatment market is segmented based on cancer type, drug class, and distribution channel:



Based on cancer type, global bladder cancer treatment market is segmented as:

Transitional cell bladder cancer
Invasive bladder cancer
Superficial bladder cancer
Squamous cell bladder cancer
Other rare types


Based on drug class, global bladder cancer treatment market is segmented as:

Chemotherapy
Alkylating agents
Plant alkaloids
Taxanes
Anti-tumour Antibiotics
Anti-metabolites
Topoisomerase inhibitors
Immunotherapy
Tumor-targeting mAbs
DC-Based immunotherapy
Peptide- and DNA-based anticancer vaccines
Immune stimulatory cytokines
Immune modulatory mAbs
Immuno suppressive metabolism Inhibitors
Pattern recognition receptor Agonists
Others


Based on distribution channel, global bladder cancer treatment market is segmented as:

Hospital Pharmacies
Retail Pharmacies
Others


As per to the National Institute of Health, approximately17,000 women  and  45,000 men for every year are diagnosed with the bladder cancer in U.S. only. Market for bladder cancer is rapidly increasing and it is anticipated to grow rapidly from 2016 to 2022 globally. As per to The American Cancer Society, in 2018, estimated bladder cancers in the United States were 79,030 new cases about 60,490 in men and 18,540 in women were diagnosed and about 16,870 deaths from bladder cancer about 12,240 in men and 4,630 in women.Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer treatment drugs. Increasing number of mergers and acquisitions, the rise in a number of collaborations and partnerships, new product launches and growing awareness about the availability of bladder cancer treatment drugs are some of the latest trends that have been observed in the market.



Global bladder cancer treatment market is segmented into five regions: North America, Europe, Asia Pacific, Latin America and The Middle East & Africa. North America followed by Europe, comprise largest market share for the bladder cancer treatment market due to the availability of advanced health care solutions, increase in the bladder cancer cases, rise in concern about bladder problems and development of health care infrastructure in the region. Asia is expected to show a high growth rate in the bladder cancer treatment drugs market during the forecast period due to rise in significant growth in bladder cancer cases, rise in need for the improved bladder cancer treatments and therapies, increasing awareness on cancer diagnosis. Growing demographics and economies in the developing countries, such as India and China, are anticipated to rise the bladder cancer treatment drugs market in Asia-Pacific region.



Some of the players in the global bladder cancer treatment market include AstraZeneca plc U.K., Bristol-Myers Squibb U.S., Celgene Corporation U.S., Eli Lilly and Company U.S., Co., F. Hoffmann-La Roche Switzerland, GlaxoSmithKline plc U.K., Novartis AG Switzerland, Pfizer Inc. U.S., and Sanofi France



In 2018, AstraZeneca received U.S. FDA accelerated approval for Imfinzi Durvalumab for the treatment of bladder cancer


In 2016, FDA has granted Biologic License Application and priority review of Roche’s Atezolizumab for the treatment of advanced bladder cancer


Report Outline:



The report provides granular level information about the market size, regional market share and forecast from 2019-2025
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. Executive summary
2. Global Bladder Cancer Treatment Market Introduction
2.1. Global Bladder Cancer Treatment Market– Taxonomy
2.2. Global Bladder Cancer Treatment Market–Definitions
2.2.1. Drug Class
2.2.2. Cancer Type
3. Global Bladder Cancer Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Bladder Cancer Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Bladder Cancer Treatment Market– Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.7. Global Bladder Cancer Treatment Market– Recent Product Launches
4. Global Bladder Cancer Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 – 2025
4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
4.2. Year-over-Year Y-o-Y Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Bladder Cancer Treatment Market, By Drug Class, 2014 - 2018 and Forecast, 2019 - 2025
5.1. Chemotherapeutic Agents Alkylating agents, Plant alkaloids, Taxanes, Anti-tumour Antibiotics, Anti-metabolites, and Topoisomerase inhibitors
5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Immunotherapy Tumor-targeting mAbs, DC-Based immunotherapy, Peptide- and DNA-based anticancer vaccines, Immune stimulatory cytokines, Immun modulatory mAbs, and Others
5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
6. Global Bladder Cancer Treatment Market Forecast, By Cancer Type, 2014 - 2018 and Forecast, 2019 - 2025
6.1. Transitional Cell Bladder Cancer
6.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Invasive Bladder Cancer
6.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Superficial Bladder Cancer
6.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
6.4. Squamous Cell Bladder Cancer
6.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.4.3. Market Opportunity Analysis
6.5. Other Rare Types
6.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.5.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.5.3. Market Opportunity Analysis
7. Global Bladder Cancer Treatment Market Forecast, By Distribution Channel, 2014 - 2018 and Forecast, 2019 - 2025
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
8. Global Bladder Cancer Treatment Market Forecast, By Region, 2014 - 2018 and Forecast, 2019 - 2025
8.1. North America
8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.5.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.5.3. Market Opportunity Analysis
8.6. Global Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Region, 2019 – 2025
9. North America Bladder Cancer Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
9.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
9.1.1.1. Chemotherapy
9.1.1.1.1. Alkylating agents
9.1.1.1.2. Plant alkaloids
9.1.1.1.3. Taxanes
9.1.1.1.4. Anti-tumour Antibiotics
9.1.1.1.5. Anti-metabolites
9.1.1.1.6. Topoisomerase inhibitors
9.1.1.2. Immunotherapy
9.1.1.2.1. Tumor-targeting mAbs
9.1.1.2.2. DC-Based immunotherapy
9.1.1.2.3. Peptide- and DNA-based anticancer vaccines
9.1.1.2.4. Immune stimulatory cytokines
9.1.1.2.5. Immune modulatory mAbs
9.1.1.2.6. Immuno suppressive metabolism Inhibitors
9.1.1.2.7. Pattern recognition receptor Agonists
9.1.1.2.8. Others
9.1.2. Cancer Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.2.1. Transitional cell bladder cancer
9.1.2.2. Invasive bladder cancer
9.1.2.3. Superficial bladder cancer
9.1.2.4. Squamous cell bladder cancer
9.1.2.5. Other rare types
9.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn Y-o-Y Growth % and Market Share %
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2019 – 2025
9.1.6. North America Bladder Cancer Treatment Market Dynamics – Trends
10. Europe Bladder Cancer Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
10.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
10.1.1.1. Chemotherapy
10.1.1.1.1. Alkylating agents
10.1.1.1.2. Plant alkaloids
10.1.1.1.3. Taxanes
10.1.1.1.4. Anti-tumour Antibiotics
10.1.1.1.5. Anti-metabolites
10.1.1.1.6. Topoisomerase inhibitors
10.1.1.2. Immunotherapy
10.1.1.2.1. Tumor-targeting mAbs
10.1.1.2.2. DC-Based immunotherapy
10.1.1.2.3. Peptide- and DNA-based anticancer vaccines
10.1.1.2.4. Immune stimulatory cytokines
10.1.1.2.5. Immune modulatory mAbs
10.1.1.2.6. Immuno suppressive metabolism Inhibitors
10.1.1.2.7. Pattern recognition receptor Agonists
10.1.1.2.8. Others
10.1.2. Cancer Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.2.1. Transitional cell bladder cancer
10.1.2.2. Invasive bladder cancer
10.1.2.3. Superficial bladder cancer
10.1.2.4. Squamous cell bladder cancer
10.1.2.5. Other rare types
10.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Others
10.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2019 – 2025
10.1.6. Europe Bladder Cancer Treatment Market Dynamics – Trends
11. Asia-Pacific Bladder Cancer Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
11.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
11.1.1.1. Chemotherapy
11.1.1.1.1. Alkylating agents
11.1.1.1.2. Plant alkaloids
11.1.1.1.3. Taxanes
11.1.1.1.4. Anti-tumour Antibiotics
11.1.1.1.5. Anti-metabolites
11.1.1.1.6. Topoisomerase inhibitors
11.1.1.2. Immunotherapy
11.1.1.2.1. Tumor-targeting mAbs
11.1.1.2.2. DC-Based immunotherapy
11.1.1.2.3. Peptide- and DNA-based anticancer vaccines
11.1.1.2.4. Immune stimulatory cytokines
11.1.1.2.5. Immune modulatory mAbs
11.1.1.2.6. Immuno suppressive metabolism Inhibitors
11.1.1.2.7. Pattern recognition receptor Agonists
11.1.1.2.8. Others
11.1.2. Cancer Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.2.1. Transitional cell bladder cancer
11.1.2.2. Invasive bladder cancer
11.1.2.3. Superficial bladder cancer
11.1.2.4. Squamous cell bladder cancer
11.1.2.5. Other rare types
11.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn,
Y-o-Y Growth %, and Market Share %
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2019 – 2025
11.1.6. Asia-Pacific Bladder Cancer Treatment Market Dynamics – Trends
12. Latin America Bladder Cancer Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
12.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
12.1.1.1. Chemotherapy
12.1.1.1.1. Alkylating agents
12.1.1.1.2. Plant alkaloids
12.1.1.1.3. Taxanes
12.1.1.1.4. Anti-tumour Antibiotics
12.1.1.1.5. Anti-metabolites
12.1.1.1.6. Topoisomerase inhibitors
12.1.1.2. Immunotherapy
12.1.1.2.1. Tumor-targeting mAbs
12.1.1.2.2. DC-Based immunotherapy
12.1.1.2.3. Peptide- and DNA-based anticancer vaccines
12.1.1.2.4. Immune stimulatory cytokines
12.1.1.2.5. Immune modulatory mAbs
12.1.1.2.6. Immuno suppressive metabolism Inhibitors
12.1.1.2.7. Pattern recognition receptor Agonists
12.1.1.2.8. Others
12.1.2. Cancer Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.2.1. Transitional cell bladder cancer
12.1.2.2. Invasive bladder cancer
12.1.2.3. Superficial bladder cancer
12.1.2.4. Squamous cell bladder cancer
12.1.2.5. Other rare types
12.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2019 – 2025
12.1.6. Latin America Bladder Cancer Treatment Market Dynamics – Trends
13. Middle East & Africa Bladder Cancer Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
13.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
13.1.1.1. Chemotherapy
13.1.1.1.1. Alkylating agents
13.1.1.1.2. Plant alkaloids
13.1.1.1.3. Taxanes
13.1.1.1.4. Anti-tumour Antibiotics
13.1.1.1.5. Anti-metabolites
13.1.1.1.6. Topoisomerase inhibitors
13.1.1.2. Immunotherapy
13.1.1.2.1. Tumor-targeting mAbs
13.1.1.2.2. DC-Based immunotherapy
13.1.1.2.3. Peptide- and DNA-based anticancer vaccines
13.1.1.2.4. Immune stimulatory cytokines
13.1.1.2.5. Immune modulatory mAbs
13.1.1.2.6. Immuno suppressive metabolism Inhibitors
13.1.1.2.7. Pattern recognition receptor Agonists
13.1.1.2.8. Others
13.1.2. Cancer Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.2.1. Transitional cell bladder cancer
13.1.2.2. Invasive bladder cancer
13.1.2.3. Superficial bladder cancer
13.1.2.4. Squamous cell bladder cancer
13.1.2.5. Other rare types
13.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
13.1.4.1. Gulf Cooperation Council GCC Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2019 – 2025
13.1.6. MEA Bladder Cancer Treatment Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis
14.2.1. AstraZeneca plc U.K.
14.2.2. Bristol-Myers Squibb U.S.
14.2.3. Celgene Corporation U.S.
14.2.4. Eli Lilly and Company U.S.
14.2.5. F. Hoffmann-La Roche Switzerland
14.2.6. GlaxoSmithKline plc U.K.
14.2.7. Novartis AG Switzerland
14.2.8. Pfizer Inc. U.S.
14.2.9. Sanofi France
15. Research Methodology
16. Key Assumptions and Acronyms


Please fill the following form to know more details about this Report




RELATED PRODUCTS



CHOOSE A FORMAT


  •  Single User Price : $ 4400
  •  Enterprise User License : $ 6600
  •  Corporate User License : $ 8900

Have A Question ?


  DOWNLOAD SAMPLE



TESTIMONIALS

I am completely satisfied with the information given in the sample pages of the report and I am waiting for the affirmative response from my peers and colleagues to purchase it.hey answered to all my queries promptly. I am highly satisfied!!
John Keats
We received a very quick response to all our queries on the RTLS report and we were also given a free consult with analyst for 15 minutes. It is refreshing (and increasingly rare) to have a new company go the extra mile to win the confidence of the customer
Ernest Hemingway
I would like to express my gratitude for the excellent service received this morning from the support team. They acknowledged my concern of adding me to the secondary user's list immediately. Thank you for this excellent, speedy and thoughtful service
Jacob Watson

CUSTOM RESEARCH

Still haven't found what you're looking for ?
Speak to our Custom Research Team